| Name | Title | Contact Details |
|---|
Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).
Second Genome is a clinical stage company with a mission to improve human health by unlocking the full potential of the microbiome. We offer the most robust approach to microbiome drug discovery and development through the deepest understanding of how the microbiome works in human health.
InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route.
Sartorius Stedim Biotech is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AmCyte Inc. is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.